Clinical Report: Updated ASTRO Guideline for Radiation Therapy in Pancreatic Cancer

Overview

The updated ASTRO guideline revises recommendations for radiation therapy in pancreatic cancer, emphasizing dose escalation and advanced treatment techniques. It incorporates evidence from recent studies, including the SMART trial.

Background

Pancreatic cancer remains a challenging malignancy with limited treatment options. The updated ASTRO guideline reflects advancements in radiation therapy and aims to enhance clinical outcomes through modern techniques and evidence-based practices.

Data Highlights

No numerical data provided in the source material.

Key Findings

• The updated guideline recommends routine elective coverage of areas at high risk for microscopic disease.
• A strong recommendation for radiation dose escalation is introduced, which was not present in the 2019 guideline.
• Long-term results from the SMART trial show a 53.6% overall survival rate at two years from diagnosis.
• Advances in technology, such as adaptive radiation therapy, allow for safer delivery of higher radiation doses.
• Locoregional failures decreased when broader target volumes were included in treatment plans.

Clinical Implications

The updated recommendations for radiation dose escalation and target volume definitions are provided to improve treatment outcomes in pancreatic cancer.

Conclusion

The updated ASTRO guideline represents a significant advancement in the approach to radiation therapy for pancreatic cancer.

Related Resources & Content

1. Chuong et al, Practical Radiation Oncology, 2026 -- Updated ASTRO Guideline on Radiation Therapy for Pancreatic Cancer
2. the asco post — ASTRO Publishes First Clinical Guideline on Radiation Therapy for Gastric Cancer
3. the asco post — ASTRO Issues Clinical Guideline on Radiation Therapy for Anal Cancer
4. the asco post — ASTRO Releases Updated Clinical Guidelines on Radiation Therapy for Patients With Bone Metastases
5. ASTRO guideline - RT for Pancreatic Cancer
6. Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas: The A021501 Phase 2 Randomized Clinical Trial | Trials | JAMA Oncology | JAMA Network
7. Stereotactic Body Radiation Therapy for Locally Advanced Pancreatic Adenocarcinoma: A Systematic Review and Meta-Analysis of Prospective Trials - PubMed